Dr. E. Jason Abel, MD FACS is the Chief of Urologic Oncology and the Robert F. and the Dolores K. Schnoes Chair in Urologic Research at the University of Wisconsin School of Medicine and Public Health. Dr Abel completed General surgery internship and Urology residency training at the University of Utah and fellowship training in Urologic Oncology at the University of Texas MD Anderson Cancer Center. Over the last decade, he has specialized in the complex surgical treatment of urologic malignancies including kidney cancer, bladder cancer, testis cancer, prostate cancer, and penile cancer. His busy clinical practice integrates minimally invasive and standard surgical approaches as well as alternatives to surgery such as thermal ablation. Dr. Abel is active in clinical, translational, and basic science research in urologic oncology. He is an author on over 100 publications in the fields of kidney, bladder, prostate and testis cancer. His laboratory research is funded by the National Institutes of Health/ National Cancer Institute and focuses on renal cell carcinoma signal transduction.

Dr. Abramson is Director of the Lymphoma Program and the Jon and Jo Ann Hagler Chair in Lymphoma at the Massachusetts General Hospital Cancer Center. He is also Associate Professor of Medicine at Harvard Medical School. Dr. Abramsonearned his medical degree from the Mount Sinai School of Medicine in New York City and a Masters Degree in Medical Sciences from Harvard Medical School.He completed a residency in Internal Medicine at the Massachusetts General Hospital in Boston, followed by a fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. Dr. Abramson is board certified in Medical Oncology. Dr. Abramson's clinical and research interests are in lymphoid malignancies, including all non-Hodgkin lymphomas, as well as Hodgkin lymphoma,and chronic lymphoid leukemias.His research involves identifying new targets for therapy in lymphomas and lymphoid leukemias, and the design and conduct of clinical trials of new cancer therapies and cellular immunotherapies in these diseases. He is a member of the American Society of Hematology, the AmericanSociety of Clinical Oncology, and a Fellow of the American College of Physicians.Dr. Abramson is the author of numerous papers and book chapters on lymphoma, and lectures widely

Dr. Carlos Becerra is a medical oncologist with the Translational Oncology Program at the Charles A. Sammons Cancer Center in Dallas, Texas. Prior to this, he was Assistant Professor of Internal Medicine at the University of Texas Southwestern Medical Center in Dallas where he served as Director of the Parkland Clinic, Director of the GI Malignancy Program, Director of the Phase I program as well as a member of the protocol and review committee, and the Pharmacy and Therapeutics subcommittee for oncology and hematology. Dr. Becerra received his medical degree from the Universidad del Valle in Cali, Colombia in 1989. He completed a residency at the Saint Francis Hospital in Evanston, Illinois where he served as chief resident in 1994. Dr. Becerra completed a fellowship in Hematology and Medical Oncology at the UT Southwestern Medical Center in Dallas, Texas in 1997 where he currently serves as volunteer faculty. An expert in gastrointestinal malignancies, Dr. Becerra is actively involved in clinical research and has authored a book chapter and numerous articles.

Al B. Benson III, M.D is a Professor of Medicine in the Division of Hematology/Oncology at Northwestern University’s Feinberg School of Medicine in Chicago, Illinois. He is also the Associate Director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, at Northwestern University. In addition, he is an Attending Physician at Northwestern Memorial Hospital, a Staff Physician at Jesse Brown VA Medical Center, and a Consultant to the Shirley Ryan Lab (Rehabilitation Institute of Chicago). Dr. Benson earned his medical degree at the State University of New York at Buffalo following which he completed an Internal Medicine Residency at the University of Wisconsin Hospitals in Madison, Wisconsin. He was an Assistant Professor of Medicine at the University of Illinois and Co-Medical Director for the National Public Health Service in Champaign, Illinois. He then served as a Clinical Oncology and Research Fellow at the University of Wisconsin Clinical Cancer Center, where he received an American Cancer Society Fellowship Award. Dr. Benson is active on numerous professional committees, often serving as an officer. He is a recipient of the American Society of Clinical Oncology (ASCO) Statesman Award (Fellow of ASCO) and has served on a number of committees. He has been a member of the Task Force on Quality of Cancer Care, the Co-Chair of ASCO’s Colorectal Cancer Guidelines Subcommittee, the Stage II Colon Cancer Guidelines Panel and the Guidelines Panel for use of Radiofrequency Ablation for Colorectal Cancer as examples. He also is the immediate past Chair of the ECOG-ACRIN Gastrointestinal Committee, Deputy Chair for Policy and Implementation, Co-chair of Cancer Care Delivery Research Committee, chair of the Data Monitoring Committee and a member of the NCI Rectal/Anal Task Force. He is chair of the International Rare Cancers Initiative (IRCI), Anal Cancers Committee, and member of the Small Intestinal Cancer Committee. In addition, he is a Past President of the Illinois Medical Oncology Society, Past President of the Association of Community Cancer Centers (ACCC), a board member and past-chair of the Board of Directors of the National Comprehensive Cancer Network (NCCN) and a member of the Board of Directors of the NCCN Foundation. He is the chair of both the NCCN Hepatobiliary Guidelines Panel and of the Colon, Rectal, Small Bowel Adenocarcinoma and Anal Panel, and a member of the Pancreatic Cancer and Neuroendocrine Panels. He is a past President of the International Society of GI Oncology (ISGIO). He has been appointed co-chair of the President’s Cancer Panel, Colorectal Cancer and Subcommittee. Dr. Benson is a member of the Executive Committee of the Patient Advocate Foundation, and the National Patient Advocate Foundation (immediate past president). Additionally, he is a medical advisory board member for Debbie’s Dream Foundation: Curing Stomach Cancer and Fight Colorectal Cancer. Dr. Benson is on the editorial board of the ASCO Connection (term completed), Journal of the National Comprehensive Cancer Network, American Health and Drug Benefits, Personalized Medicine in Oncology, Journal of Comparative Effectiveness Research, and Gastrointestinal Cancer research among others. His most recent national awards include the NCCN Rodger J. Winn award, the ACCC Outstanding Achievement in Clinical Research Award and the CancerCare Physician of the Year Award. Dr. Benson’s research is primarily in the areas of gastrointestinal cancer clinical trials, biologic therapies, phase I cancer clinical trials, health services research, and cancer guideline development. He has authored or coauthored numerous reports, reviews and book chapters focusing on these topics. His research in biologics, cancer therapy, and cancer prevention has been awarded funding from a variety of sources including the NIH.

Sanjeev Bhalla, MD, associate professor of radiology and chief of the Section of Cardiothoracic Imaging, co-chief of emergency radiology and body computed tomography at Washington University’s Mallinckrodt Institute of Radiology. He is highly sought after for consultations, even by members of his own department, particularly in the areas of cardiothoracic and pulmonary imaging. He has been listed in Best Doctors in America since 2005. He is held in equally high regard as an outstanding teacher, currently serving as director of the emergency medicine resident rotation in diagnostic radiology and advisor for medical students going into radiology. Bhalla is highly active in all of the major national radiology societies and is a frequent guest lecturer nationwide and internationally.

Dr. Bilen serves as Associate Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Bilen joined the clinical staff at Winship Cancer Institute as a practicing physician in July 2016. He is actively involved in clinical research and patient care in the area of genitourinary cancers and serves as the Associate Medical Director of the Phase I Unit at Winship Cancer Institute. He works closely with the Fellowship Program of the Department of Hematology and Medical Oncology by educating fellows on genitourinary oncology. He also serves on the Winship Clinical and Translational Review Committee and Grady Clinical Research Committee. Dr. Bilen holds professional memberships with American Association for Cancer Research and American Society of Clinical Oncology. Dr. Dr. Bilen worked with Dr. Sue Hwa Lin on developing biomarkers and therapeutic strategies that can be applied in clinical settings to promote early detection and to improve treatment options for prostate cancer bone metastasis. Dr. Bilen continued to focus on genitourinary malignancies after becoming a clinical fellow at UT MD Anderson Cancer Center where he worked on several projects in clinical and translational research. In 2015, he was selected to participate in the AACR/ASCO Vail workshop.Dr. Bilen has published a number of peer-reviewed original papers and reviews in leading journals including Cancer Research, Molecular Cancer Research, FASEB J, Journal of Pathology, Cancer and Clinical and Experimental Metastasis and has authored or co-authored several abstracts for presentations at professional meetings.

Thomas Buchholz, MD, is medical director of Scripps MD Anderson Cancer Center, a comprehensive and clinically integrated cancer care program in San Diego. In his leadership role, Dr. Buchholz is responsible for directing all clinical activities and programs at Scripps MD Anderson Cancer Center, ensuring care is efficient, effective and supports the patient-centered mission of the program. He leads the development of clinical research activities within the program, including collaboration with MD Anderson clinical trials and other industry-sponsored and investigator-initiated trials. In addition to his leadership responsibility, Dr. Buchholz maintains a clinical practice focused on radiation oncology and breast cancer. He has made significant scientific and academic contributions over the course of his career. His breast cancer research has been published in more than 350 peer-reviewed journals and he has written 97 editorials, 48 invited articles and numerous book chapters. He is board certified by the American Board of Radiology and the National Board of Medical Examiners. He served a six-year-term as the co-chair of the Breast Cancer Steering Committee of the National Clinical Trials Network of the National Cancer Institute. Dr. Buchholz spent 20 years in Houston at The University of Texas MD Anderson Cancer Center. He previously held a variety of clinical, research, academic and administrative leadership positions with MD Anderson, including division head and department chair of radiation oncology and serving as executive vice president and physician-in-chief.

Dr. Butler received her residency training in Diagnostic Radiology and fellowship in Breast Imaging at Northwestern Memorial Hospital in Chicago, Illinois. After 10 years in private practice in the Chicago area, she returned to academic medicine at Yale New Haven Hospital and joined the medical faculty of Yale School of Medicine in 2009. Dr. Butler’s areas of research interest include digital breast tomosynthesis, screening breast ultrasound, and AI in breast imaging. In addition, she served as national co-PI for a multi-institutional clinical trial of opto-acoustic breast imaging, recognized as a high-impact clinical trial at the 2017 meeting of the RSNA and published in Radiology and the American Journal of Roentgenology. Dr. Butler has actively pursued a teaching role at Yale and within the radiology community at large. She is currently serving as Associate Program Director for Yale School of Medicine’s Residency in Radiology and Biomedical Imaging. After completing a medical education fellowship at the Yale School of Medicine, she founded the Yale Undergraduate Shadowing Program at the Smilow Breast Center. She participated in revising the medical school curriculum of the Yale School of Medicine, where she teaches first-year medical students, introducing Diagnostic Radiology in early medical education. Dr. Butler has received awards for excellence in teaching from her own residents at Yale and held several visiting professorships in Connecticut at community hospital-based residency programs. She has lectured at regional, national, and international CME meetings and served on national committees, including the RSNA Breast Imaging Exhibit Review Panel and ARRS Education Evaluation Committee. Dr. Butler is also a reviewer for the American Journal of Roentgenology, European Journal of Radiology, Acta Radiologica, Journal of Breast Imaging, and RadioGraphics, for which she has received multiple Editor’s Recognition Awards.

Dr. Camidge’s main clinical and research interests are thoracic malignancies and developmental therapeutics. The discoveries he and his team have made have changed the standard of care for the treatment of lung cancer multiple times. He has authored over 250 academic publications, including in the Journal of Thoracic Oncology, Lancet Oncology, and New England Journal of Medicine. He has received numerous awards including the Bonnie J. Addario International Lectureship Award and The Lung Cancer Foundation’s Breath Away From The Cure Award. In 2017, 2018 and 2019, he was internationally recognized as a highly cited researcher ranked in the top 1% of all Clinical Medicine by Clarivate Analytics Web of Science. He is the National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC), Co-chair of the Elsevier/VIA Oncology Lung Cancer PathwaysCommittee and a past-member of the National Comprehensive Cancer Network Lung Cancer Committee.

Scott Celinski, MD, FACS focuses on the surgical treatment complex pancreatic, hepatobiliary and abdominal malignancies. Dr. Celinski received his MD from Baylor College of Medicine. He completed a residency in General Surgery fellowship in Critical Care at George Washington University Medical Center. He then went on to complete fellowships in Surgical Oncology and Hepatobiliary Surgery at the University of Pittsburgh Medical Center. Dr. Celinski serves as the co-Medical Director of the Pancreatic Cancer Research and Treatment Center at Baylor Scott & White Charles A. Sammons Cancer Center – Dallas. His research interests are neoadjuvant therapy for pancreas cancer and early detection in high-risk patients.

Yi-Bin Chen grew up in New Jersey. He majored in molecular biophysics and biochemistry, earning a B.S./M.S.at Yale University before attending medical school at Harvard Medical School. Subsequently, he did his internship and residency at Massachusetts General Hospital, including an additional year as Chief Resident. This was followed by a fellowship in hematology/oncology at the Dana-Farber Mass General Brigham combined program. In 2008, he joined the staff of the Blood & Marrow Transplant (BMT) Program at the MGH Cancer Center, has served as Director of Clinical Research since 2012 and was named overall Program Director in 2016. In 2020, he was named Director of the Hematopoietic Cell Transplant and Cell Therapy Program, uniting the programs of conventional transplant and emerging cellular therapies. His clinical interests mainly revolve around improving the outcomes of patients undergoing autologous and allogeneic stem cell transplantation. He has led original clinical trials involving all aspects of BMT, including conditioning regimens, alternative graft sources, novel approaches concerning the prevention and therapy of acute and chronic graft-vs-host disease (GVHD) and the use of maintenance therapies after BMT. He collaborates extensively with local and national colleagues as well as industry in addition to developing his own original clinical trials. He currently lives in Needham, MA with his wife and two children.

Christopher Crane, MD, is Gastrointestinal Section leader in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center. His primary research interest is in using novel technologies to deliver and ablative dose of radiation for inoperable pancreatic and liver cancers. He has conducted clinical trials in pancreatic, liver, anal, and rectal cancers and represented the field of radiation oncology on the NCI’s Pancreatic Cancer Task Force and the Gastrointestinal Steering Committee for the past 10 years and is the former Chairman of the Gastrointestinal Committee of the Radiation Therapy Oncology Group, and the NRG Oncology’s Non-colorectal GI Committee. He has been recognized 4 times with major awards for excellence in education and 18 consecutive years by his peers as one of the Best Doctors in America.

Walter J. Curran, Jr., MD, FACR, FASCO, is the Executive Director of the Winship Cancer Institute of Emory University, the first and only National Cancer Institute-designated comprehensive cancer center in the state of Georgia. He also serves as the Lawrence W. Davis Professor and Chairman in Emory's Department of Radiation Oncology. Dr. Curran has been a principal investigator on many National Cancer Institute (NCI) grants and is considered an international expert in the management of patients with locally advanced lung cancer and malignant brain tumors. He currently serves as a group chairman and a principal investigator of NRG Oncology, the largest of the five National Cancer Institute-funded clinical trials network group.Dr. Curran is the first radiation oncologist to serve as Director of a National Cancer Institute-designated cancer center. He is the only individual currently serving as director of an NCI-designated comprehensive cancer center and as group chairman of an NCI-supported cancer cooperative group. He was also named a Georgia Research Alliance Eminent Scholar and Chair in Cancer Research in 2013. Dr. Curran is a Fellow and Gold Medal Recipient (2016) in the American College of Radiology. He is a Fellow and serves as a board member of the American Society of Clinical Oncology and as a standing member of NCI's Clinical Trials Advisory Committee. He serves as a member of the external scientific advisory committees of two NCI designated comprehensive cancer centers (Simmons CC at UT Southwestern and Siteman CC at Washington University) and two developing cancer centers (University of Florida and Stevenson CC at University of Oklahoma). He was ranked among the top 10 principal investigators in terms of overall NCI funding in 2013 and among the leading twenty investigators in terms of overall NIH funding as principal investigator in 2013.Before joining Emory, Dr. Curran was Professor and Chairman of Radiation Oncology at Thomas Jefferson University in Philadelphia and Clinical Director of Jefferson's Kimmel Cancer Center.Dr. Curran graduated with honors from Dartmouth College, received his MD degree from the Medical College of Georgia, and is a Board Certified Radiation Oncologist. Curran completed his residency in theDepartment of Radiation Therapy at the University of Pennsylvania Medical Center and his internship in internal medicine at Presbyterian University of Pennsylvania Medical Center in Philadelphia.Dr. Curran has led several landmark clinical and translational trials in the areas of lung cancer and malignant brain tumors, and is responsible for defining a universally adopted staging system for patients with malignant glioma.

Dr. Derweesh is Professor of Radiology and has built an academic practice in urologic oncology and kidney surgery, specializing in laparoscopic surgery and kidney-preserving treatment for kidney cancer (laparoscopic and open partial nephrectomy, cryoablation). His research interests include kidney ischemia and reconstruction, as well as the development of new techniques and technologies for minimally invasive surgery.

Dr. Timothy R. Donahue is a Professor in the Department of Surgery, Chief of the Division of Surgical Oncology, and Vice Chair for Surgical Cancer Care at the David Geffen School of Medicine at UCLA. He is a very busy pancreatic surgeon. He holds a dual appointment in the Department of Molecular and Medical Pharmacology where his laboratory is located. He is the Surgical Director of the UCLA Pancreatic Cancer Program and the UCLA Neuroendocrine Tumor Program. He has successfully bridged his pancreatic surgery practice with his NCI/NIH funded pancreatic cancer research program. He is an expert in pancreatic cancer tumor biology and metabolism and aims to discover novel therapeutics and personalized treatment strategies for pancreatic cancer patients. Specifically, his laboratory studies the impact of the tumor microenvironment, and the cross-talk between metabolism and signaling to identify co-dependencies of pancreas cancer tumor cells. He is responsible for generating many human-derived pancreatic resources at UCLA – most notably the primary human tumor xenograft model, primary cell and organoid cultures, and a well-annotated repository of human pancreatic cancer specimen. In all, he has the resources, faculty position, and skills to serve as the Principal Investigator of this grant application.

Dr. Alexandra Drakaki's primary research interest is to evaluate the role of non-coding RNAs in genitourinary (GU) malignancies, including bladder, prostate and kidney cancers and to develop novel therapeutics targeting these non-coding RNAs.Non-coding RNAs consist of a novel category of genes that are not translated into proteins and act as regulators of gene expression. The two main categories of non-coding RNAs include primarily the microRNAs and the long non-coding RNAs (lncRNAs). MicroRNAs are small RNA molecules, 18-25 nucleotides long, that act as negative regulators of gene expression through binding in the 3' untranslated region (UTR) of coding genes. On the other hand, lncRNAs are >200 nucleotide long, acting as scaffolds and mediators of protein complexes activity.Both microRNAs and lncRNAs play significant role in oncogenesis through regulation of key signal transduction pathways, such as the PI3K/AKT pathway, the Wnt pathway and cell cycle. Therefore, the goal of Drakaki's research program is to identify the non-coding RNAs that are deregulated in GU cancers and develop chemically modified oligonucleotide inhibitors to manipulate their expression levels. Her ultimate aim is to examine these new drugs in GU preclinical models and evaluate their efficacy in human clinical trials.

Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, was recruited to Vanderbilt University Medical Center from The University of Texas MD Anderson Cancer Center in Houston.Eng is co-director of the Gastrointestinal Program and co-leader of the Vanderbilt-Ingram Cancer Center Gastrointestinal Cancer Research Program. She serves on multiple committees for the National Cancer Institute (NCI), Southwestern Oncology Group (SWOG) and Eastern Cooperative Oncology Group (ECOG).Eng has been a principal investigator of innumerable national and international trials, NCI-funded trials and major pharmaceutical-sponsored trials. Her primary clinical research interests include clinical trials involving innovative drugs for the treatment of colorectal, anal, and appendiceal cancers. She has a specific interest in young colorectal cancer patients as well as the role of immunotherapy in HPV-associated cancers. She has published multiple publications in these GI malignancies.Nationally, Dr. Eng has served in multiple leadership roles for ASCO, ASCO GI, ECOG, and the NCI Rectal/Anal Task Force. She has most recently been chosen to serve as the Vice-Chair for the SWOG GI Committee and the NCI GI Steering Committee.Eng received her medical degree from Hahnemann University School of Medicine in Philadelphia. She completed residency in internal medicine at Rush University Medical Center and a fellowship in hematology and oncology at University of Chicago Medical Center. She was with MD Anderson for 17 years.Dr. Eng has a personal touch, and as a key opinion leader in GI cancer, especially those occurring in younger adults, you are confident that her guidance will be the best a patient can get, anywhere, period.

Dr.Richard Finn is a professor of Medicine at the Geffen School of Medicine at UCLA in the Department of Medicine, Division of Hematology/Oncology. He was an undergraduate at UCLA where he was involved with early laboratory studies investigating the HER2 oncogene and the development of monoclonal antibodies to this target in breast cancer with Dr. Dennis Slamon. He participated in the pre-clinical studies that defined the clinical candidate that eventually humanized and became the FDA approved agent trastuzumab (Herceptin). He went on to medical school at USC then returned to UCLA for his clinical training in Internal Medicine and then Hematology/ Oncology. He currently splits his time between patient care and directing the Translational Research Laboratory in the Division of Hematology/Oncology. His research interests are focused in the development of targeted therapeutics for solid tumors across histologies to support the larger efforts of the department. His personal interests lie in the development of these targeted agents in Hepato-biliary and breast cancers. He has two-half days dedicated to patient care, one of which is as a leader in the multi-disciplinary hepato-biliary cancer program at UCLA where he is involved with clinical studies aimed at bringing novel therapeutics into the treatment of patients with these malignancies.

Dr. Seth Force is currently the Kamal A. Mansour Professor of General Thoracic Surgery and the Chief of the Section of Thoracic Surgery at Emory University in Atlanta, Georgia. Dr. Force joined the thoracic group at Emory in 2003 after completing his thoracic residency at Washington University in St. Louis. Prior to this he completed his general surgery residency at the University of Pennsylvania where he spent two additional years, in Dr. Larry Kaiser’s Thoracic Oncology Research Laboratory, studying the effects of novel gene therapy treatments on malignant mesothelioma. Dr. Force is an active member in the Society of Thoracic Surgeons and the American Association of Thoracic Surgeon where he co-chaired the General Thoracic Postgraduate Course in 2017. He additionally has served on the AATS Education Committee. Dr. Force also served as the Surgical Director for the Lung Transplant Program, at Emory, from 2003 until 2019 however, his main interests lie in thoracic oncology and in particular developing and furthering minimally invasive techniques for the treatment of mediastinal, pulmonary, esophageal and pleural diseases. Dr. Force is active in clinical research and has author or co-authored over 100 peer reviewed manuscripts. He is also currently a member of the Editorial Board for the Annals of Thoracic Surgery.

Dr. Forsberg received his bachelor’s degree from Washington University in St. Louis. He completed medical school at the University of Colorado School of Medicine. He went to New York for his medical training and completed his residency in Internal Medicine at the Weill-Cornell Medical College/New York-Presbyterian Hospital. He served as chief medical resident at Memorial Sloan Kettering Cancer Center before returning to Cornell for his fellowship training in Hematology and Medical Oncology. In 2016 he returned to Colorado to join the blood cancer and BMT program at the University of Colorado. Dr. Forsberg’s clinical and research focus centers on multiple myeloma and related diseases including amyloidosis and Waldenstrom’s Macroglobulinemia. He serves as the principal investigator on various clinical trials. He has published and presented his work at the national and international level.

Tyler Fraum is Assistant Professor of Diagnostic Radiology and Nuclear Medicine at Washington University School of Medicine. His focus is in diagnostic radiology, nuclear medicine, PET, CT, MRI, PET/MRI. Dr. Fraum's research interests include applications of oncological imaging modalities for hepatocellular carcinoma, cervical cancer and rectal cancer.

Michelle S. Ginsberg, MD is Vice Chair for Education and Director of Cardiothoracic Imaging in the Radiology Department at Memorial Sloan Kettering Cancer Center. She is a Professor of Radiology at Weill Cornell Medical College. Dr. Ginsberg received her BS and MD degrees at Brown University as part of 7-year Program. She completed her Radiology residency at Montefiore/Albert Einstein College of Medicine in 1995 and an Oncologic Imaging fellowship at Memorial Sloan Kettering Cancer in 1996. Dr. Ginsberg was named the 2018 New York Roentgen Society Distinguished Radiologist. She has served as President of the New York Roentgen Society and has been named Castle Connolly Top Doctors, New York Metro Area for the past 11 consecutive years and Top Doctors, New York Magazine for the past 6 years. Dr. Ginsberg’s research focuses on detection, characterization and measurement of thoracic malignancies and improving techniques to assess tumor response. She has authored more than 150 original peer reviewed publications, invited reviews and chapters.

Dr. Gradishar is chief of the Division of Hematology and Oncology in the Department of Medicine and Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine. He is also director of Lurie Cancer Center’s Maggie Daley Center for Women’s Cancer Care, where he develops and implements clinical trials of new therapeutic approaches for breast cancer. Gradishar has served as chair of the Lurie Cancer Center’s Lynn Sage Breast Cancer Symposium, a nationally recognized, four-day meeting for the practicing clinician, since its inception in 1998. His research focuses on the development of adjuvant therapies and novel therapeutics for the treatment of breast cancer. A fellow of the American College of Physicians and a fellow of the American Society of Clinical Oncology (ASCO), Gradishar is also a member of the American Association for Cancer Research and the American Federation for Clinical Research. He has held numerous leadership positions in ASCO, been a member of numerous study sections for funding agencies including the Department of Defense, NIH, Komen Foundation and American Cancer Society. He has served as a consultant to the FDA Oncology Drug Advisory Committee. He is a member of the Breast Cancer Core Committee of the Eastern Cooperative Oncology Group. Gradishar is chair of the National Comprehensive Cancer Network Breast Cancer Guideline Panel and a member of the Breast Cancer Prevention Panel. He was recently appointed chair of the Breast Cancer Working Group for the Moonshot 2020 Initiative, which will spearhead the development of novel therapeutics for the treatment of breast cancer. Gradishar is a member of the editorial boards of the Journal of Clinical Oncology, Clinical Breast Cancer, Current Treatment Options in Cancer, European Journal of Medical Oncology, Oncology and editor-in-chief of NEJM Journal Watch: Oncology and Hematology.

Kristin Higgins, M.D., specializes in the treatment of lung and head and neck cancers. She completed residency in Radiation Oncology at Duke University, as well as an internship in internal medicine. She attended medical school at Tulane Univer- sity in New Orleans, LA. She earned a B.S. in neuroscience at Van- derbilt University and graduated magna cum laude. Throughout her training Dr. Higgins received numerous honors, including in- duction into Alpha Omega Alpha Honor Medical Society, and the Roentgen Resident/Fellow Research Award at Duke University, and the ASCO Bradley Stuart Beller Merit Award. Dr. Higgins is an Associate Professor within the Emory School of Medicine and serves as the Medical Director of Radiation Oncolo- gy at the main campus location. She leads numerous Winship Clinical Trials that examine innovative treatment approaches in the treatment of lung cancer. One such clinical trial is LU005, A NRG Oncology/Alliance study comparing chemoradiation with or without immunotherapy for limited stage small cell lung cancer. This clinical trial is funded by the National Cancer Institute and provides a novel treatment approach for patients with newly diagnosed small cell lung cancer. Dr. Higgins has authored and coauthored over 60 scientific, peer-reviewed manuscripts and abstracts and given many oral presentations at national and international meetings. Dr. Higgins is a member of multiple professional organizations including the American Society for Radiation Oncology, the American Board of Radiology, the International Association for the study of Lung Cancer, The American Society of Clinical Oncology, and the Radiation Therapy Oncology Group. In her free time, Dr. Higgins enjoys spending time with her husband Darren and her small children, Hunter and Parker. She also enjoys running, traveling, reading, fine dining, and wine tasting.

Sara A Hurvitz, MD, is Professor of Medicine at the University of California, Los Angeles (UCLA); co-director of the Santa Monica-UCLA Outpatient Oncology Practice; Medical Director of the Clinical Research Unit of the Jonsson Comprehensive Cancer Center at UCLA; and Director of Breast Oncology. Dr. Hurvitz earned her MD from the University of Southern California. She served internship/residency at UCLA, was Chief Resident of internal medicine and completed a hematology-oncology fellowship at UCLA in 2006. Dr. Hurvitz received board-certification in internal medicine, hematology, and medical oncology. Dr. Hurvitz has won numerous awards over the past few years, among them the Marni Levine Memorial Breast Cancer Research Award 2008 through 2015. She has an active clinical practice specializing in the treatment of women with breast cancer. She is involved in designing, implementing and leading multiple national and international clinical trials testing new targeted therapies and also leads the preclinical evaluation of novel breast cancer targets in the Translation Oncology Research Laboratory at UCLA.

Mohammad Jahanzeb is Founder and Managing Partner at Florida Precision Oncology Research and Consulting, LLC. Dr. Jahanzeb currently serves as the Chief Medical Oncology Scientific and Strategic Advisor at 21st Century Oncology. Prior to that he was Professor of Medicine and served as the Medical Director of University of Miami's Sylvester Comprehensive Cancer Center's Deerfield Beach Campus and as an Associate Center Director for Community Outreach. An international lecturer on issues related to breast and lung cancers, Dr. Jahanzeb has given more than 900 lectures as an invited speaker and has authored or contributed to more than 200 original reports, book chapters, reviews, and abstracts. Dr. Jahanzeb is board certified in Medical Oncology and limits his practice, as well as clinical research, to cancers of the lung and breast. He received his medical degree with high honors from King Edward Medical College at the University of Punjab in Lahore, Pakistan. Dr. Jahanzeb is a fellow of the American College of Physicians and belongs to several professional societies including the American Society of Clinical Oncology, where he served as the Chair for Quality Oncology Practice Initiative Steering Task Force and is the Founding and Immediate Past Chair for their International Quality Task Force. He is currently a member of the FLASCO Board of Directors where he has previously served as the Chair of its Continuing Medical Education Committee for 3 years. He has also previously served on the Board of Directors, and the Expert Panels for Lung Cancer and Breast Cancer of the National Comprehensive Cancer Network between 2003 and 2010.

Maxine Jochelson, M.D. is a diagnostic oncologic radiologist with special interest in breast imaging. She is currently Chief of radiology at the new Breast and Imaging Center at Memorial Sloan-Kettering Cancer Center, where she is an associate attending, and an assistant professor of radiology at the Cornell Weill Medical School.Dr. Jochelsonis a graduate of New York Medical College. She completed her medical internship and radiology residency at Los Angeles County Hospital, USC Medical Center in Los Angeles, CA, followed by a clinical and research fellowship in radiology at Brigham and Women's Hospital, Dana-Farber Cancer Institute in Boston, MA,where she remained on the faculty for 9 years. She subsequently served as acting director and then as director of the Division of Oncodiagnostic Radiology, Dana-Farber Cancer Institute. After returning to California, she was a staff radiologist at the Hoag Memorial Hospital in Newport Beach and then served as director of mammography and oncologic radiology at Cedars-Sinai Medical Center in Los Angeles. Dr. Jochelson served as co-director of the San Fernando Valley Women’s Center at Tarzana Medical Center and as medical director of radiology at Good Samaritan Hospital.Dr. Jochelson is currently conducting research on new breast imaging techniques such as contrast enhanced mammography and positron emission mammography. She is also interested in determining the most cost-effective methods for staging malignancies, especially breast cancer.Dr. Jochelson has always been an advocate for cost-effective and excellent patient care, speaking at many local and national venues, including several television appearances.

Manali Kamdar serves as the Associate Professor, Clinical Director lymphoma services at the University of Colorado Hospital Cancer Center. Dr. Kamdar's clinical and research interests include B-cell lymphomas, particularly refractory DLBCL, Mantle cell lymphomas and other indolent lymphomas. Besides seeing lymphoma patients in clinic, Dr. Kamdar's research involves conducting early Phase I/II clinical trials involving novel drugs including immunotherapy and combinations in these diseases.

Dr. Larry L. Kestin has authored over 400 peer reviewed journal publications, abstracts and book chapters. He is a radiation oncology written and oral boards examiner for the American Board of Radiology and Chair of the Lung/Sarcoma section. He is a member of the NCI Thoracic Malignancy Steering Committee and has been a member of multiple ASTRO Committees. He has held academic appointments as a full professor at Oakland University and UCLA and currently a Clinical Professor at Wayne State University as well as he was the Program Director for the Department of Radiation Oncology at William Beaumont Hospital. He is actively involved in clinical research and has served as Principal Investigator for many local as well as national clinical trials. He has been selected as “Best Doctors in America”, Castle Connolly “Top Doctors” and Hour Detroit Magazine “Top Docs” on numerous occasions.

Dr. Kies is a board-certified diagnostic and interventional radiologist with special interest and expertise in interventional oncology, a subspecialty field of interventional radiology that deals with the diagnosis and treatment of cancer and cancer-related problems using targeted minimally invasive procedures performed with image guidance. He has a particular interest in the management and treatment of primary and secondary liver cancers utilizing percutaneous tumor ablation and/or catheter directed intra-arterial therapies such as transarterial chemoembolization and yttrium-90 radioembolization. He also has experience using these techniques for the treatment of renal cancers, lung cancers, and osseous metastatic disease. Additional interests of note include vertebral augmentation for both benign and malignant spinal compression fractures, percutaneous biliary interventions for benign and malignant obstruction, portal vein embolization prior to hepatic resection, management of bleeding complications and encephalopathy related to portal hypertension, complex IVC filter retrieval, uterine fibroid embolization (UFE), and prostate artery embolization (PAE). He is also an expert at performing arterial procedures through the wrist (radial artery access), which affords patients more comfort and faster time to discharge. Particularly useful applications for this technique include transradial liver therapies, transradial uterine fibroid embolization (TRUFE), and transradial PAE. Dr. Kies is a partner of Piedmont South Imaging, a private radiology group providing services to Piedmont Fayette and Newnan Hospitals. He serves as the section chief of interventional radiology.

Dr. Tari A. King is the Anne E. Dyson Professor of Surgery at Harvard Medical School, the chief of the Division of Breast Surgery and the associate chair of multidisciplinary oncology in the Department of Surgery at Brigham and Women's Hospital, and the chief of breast surgery at Dana-Farber/Brigham and Women's Cancer Center. She is also the director of the Breast Cancer Personalized Risk Assessment, Education and Prevention (B-PREP) Program at Brigham and Women's Hospital. Dr. King received her medical degree from University of Colorado Health Sciences Center and completed a general surgery residency at Ochsner Clinic Foundation Hospital (now Ochsner Medical Center) in New Orleans. Dr. King completed both a surgical research fellowship and a breast surgery clinical fellowship at Memorial Sloan Kettering Cancer Center. Her clinical and research efforts focus on improving clinical management strategies for women at high risk of developing breast cancer with a special emphasis on lobular carcinoma in situ and atypical hyperplasia. She also has an interest in the role of surgery in stage IV breast cancer and through the Translational Breast Cancer Research Consortium (TBCRC) she successfully initiated and completed accrual to a multi-center trial addressing this issue. She has received several awards to support her work on high-risk breast lesions, including the Society of Surgical Oncology (SSO) Clinical Investigator Award in Breast Cancer Research (2008), a Career Catalyst Award (2009), an Investigator Initiated Research Award (2012) and a leadership grant from the Susan G. Komen for the Cure Foundation (2016). Most recently she was awarded a BWH Precision Medicine Award (2018-19). Dr. King currently serves on the Steering Committee for the TBCRC, the NCI Breast Oncology Local Disease Task Force and the 2019 AACR Cancer Progress Report. She is also a member of Executive Council and the chair of the Quality Committee for the SSO.

Dr. Klempner is an Assistant Professor at Massachusetts General Hospital and Harvard Medical School and leads the gastric and esophageal program. His clinical and translational research is centered on cancer genomics, acquired resistance to targeted therapies and the intersection of genomics and immune mediated therapies to identify novel therapeutic approaches and biomarkers in gastroesophageal cancers. He serves on the NRG non-colorectal committee, NCCN guideline committees for gastric and esophageal cancers, and his works is supported by Stand Up 2 Cancer, NCI/NIH, AACR, and he currently serves as the AGA Research Foundation’s Gastric Cancer Foundation Ben Feinstein Memorial Research Scholar Award in Gastric Cancer. Dr. Klempner completed his residency in internal medicine at Brigham and Women’s Hospital/Harvard Medical School, followed by a combined hematology-oncology fellowship at Beth Israel Deaconess Medical Center/Harvard Medical School. While at Harvard Dr. Klempner studied the mechanisms of resistance to targeted therapies in tumor cells in the lab of Dr. Lewis Cantley, PhD. He has published over 100 original manuscripts, review articles, editorials and book chapters and his work has been published in multiple journals including Journal of Clinical Oncology (JCO), Cancer Discovery, Lancet Oncology, JAMA Oncology, Annals of Oncology and others. A complete list of publications can be found here.As a member of the gastrointestinal cancer group at MGH Dr. Klempner works in a multidisciplinary team to optimize and individualize treatment using molecular characterization across all stages of GI cancers. He conducts clinical trials and translational research with new targeted agents and immune therapies and is active in gastroesophageal cancer advocacy and education.

Dr. Kooby is an experienced Surgical Oncologist who specializes in treating upper gastrointestinal malignancies, such as tumors of the pancreas, liver, bile ducts, stomach and esophagus. Dr. Kooby is currently the Vice Chief of Staff and an Executive Board member of Emory Saint Joseph’s Hospital, and he also leads the 20-member Emory University Department of Surgery group at that location. He serves on several national committees pertaining to surgical care of patients with cancer. He has extensive research and mentoring experience, and his research focuses on improving surgical technique and assessing outcomes for patients with neoplasms of the hepatobiliary, pancreas and upper gastrointestinal tract. Dr. Kooby performed both prospective and retrospective assessments of open and minimally invasive methods of surgical resection, and collaborates with investigators at Emory, the United States, and around the world. He his team has published numerous high impact papers on various aspects of treating patients with upper gastrointestinal tumors, including a recent analysis of surgical margin assessment for pancreatic cancer cases. He has led international meetings on minimally invasive pancreatic surgery and he was the Program Chair for the America’s Hepato-Pancreato-Biliary Association in 2019. He is on the American Joint Committee on Cancer staging committee for hepato-pancreato-biliary malignancies for the 8th edition of the cancer-staging manual. He is also an Associate Editor for the pancreatic sections of two leading surgical oncology journals.

Dr. Levy is Associate Professor at the Johns Hopkins School of Medicine and was recruited to be Clinical Director of The Sidney Kimmel Cancer Center, Johns Hopkins Medicine at Sibley Hospital in Washington DC. Dr Levy is a physician scientist who is currently leading global immunotherapy trials. In addition, he currently leads multiple targeted therapy trials with a specific interest in EGFR mutant lung cancer. Dr. Levy has played an integral role on several American Society of Clinical Oncology (ASCO) committees and currently serves as editor in chief for the ASCO Self Evaluation Program (SEP). He also serves on the Lungevity Scientific Advisory board as well as the IASLC’s International Lung Cancer Foundation Advisory Board. He is an ad hoc reviewer for Clinical Cancer Research (CCR), Annals of Oncology and the Journal of Clinical Oncology. He was selected as one of only 15 oncologist in the country to the prestigious ASCO Leadership Development Program whose mission is to identify and develop future leaders of ASCO.

Dr. Lieu joined the University of Colorado School of Medicine faculty in July 2011. He trained in internal medicine at the University of Colorado, where he served as a Chief Medical Resident. He completed his fellowship training in medical oncology at the University of Texas MD Anderson Cancer Center and also served as the Chief Medical Oncology Fellow. Dr. Lieu is the Associate Director for Clinical Research and Director of GI Medical Oncology at the University of Colorado Cancer Center, the Vice-Chair of the National Cancer Institute Colon Cancer Task Force, and he serves on the National Comprehensive Cancer Network (NCCN) Panel for Neuroendocrine Cancers.Dr. Lieu is a member of the Developmental Therapeutics (phase I clinical trials) and Gastrointestinal (GI) Medical Oncology Program. These comprehensive programs include multidisciplinary cancer clinics, tumor boards, and research endeavors. Dr. Lieu is interested in resistance mechanisms to targeted therapy in GI cancers, and he was awarded the Conquer Cancer Foundation Career Development Award, NIH K23 grant, and a NIH R01 grant to study targeted therapies in colorectal cancer. Dr. Lieu is also investigating novel therapeutic strategies to more effectively treat and prevent colorectal cancer in young adults.

Dr. Reshma Mahtani is an esteemed medical oncologist at the Miami Cancer Institute and serves as the Chief of Breast medical oncology for Baptist Health Wellness and Medical Complex. Her area of expertise is exclusively focused on the treatment of breast cancer.

Previously, Dr. Mahtani was an associate professor of medicine and co-leader of the Breast Cancer Site Disease Group at the University of Miami Miller School of Medicine, where she also directed community outreach efforts. With a passion for clinical research, she has contributed significantly to the field of breast cancer through numerous peer-reviewed publications and presentations at various global conferences. Dr. Mahtani has secured funding from various organizations and has served on national committees to recognize cancer clinics providing quality care.

Outside of her research, Dr. Mahtani cherishes spending time with her patients, educating them about their breast cancer and treatment options, and providing them with hope through clinical trials and the latest targeted therapies. She has also initiated several healthcare access and community advocacy programs and founded a medical education initiative to ensure physicians in South Florida are up-to-date with the latest cancer treatments.

When not practicing medicine, Dr. Mahtani enjoys traveling the world with her loved ones.

Terry Mamounas, MD, MPH, FACS, received his medical degree from the University of Athens Medical School in Athens, Greece, in 1983 and a Masters of Public Health from the University of Pittsburgh in 1989. He completed his general surgery residency at McKeesport Hospital in Pennsylvania. He then completed a clinical oncology research fellowship at the University of Pittsburgh and a surgical oncology fellowship at the Department of Surgical Oncology, Roswell Park Cancer Institute in New York. He is currently the Medical Director or the Comprehensive Breast Program at Orlando Health Cancer Institute and Professor of Surgery at the University of Central Florida. Dr. Mamounas has authored and co-authored more than 430 abstracts, peer-reviewed manuscripts and book chapters and has given numerous lectures at national and international meetings. As part of the National Surgical Adjuvant Breast and Bowel Project and NRG Oncology, his clinical research has been funded over the past 25 years by several National Cancer Institute grants and more recently by a Komen for the Cure grant. He has served on the editorial boards of several oncology journals and is a past associate editor of the Journal of Clinical Oncology. He has received several awards and distinctions and has been listed in The Best Doctors in America consistently since 2001. He is considered one of the nation's best cancer physicians. Dr. Mamounas holds memberships in several professional societies, including the American College of Surgeons, the Society of Surgical Oncology and the American Society of Clinical Oncology.

Viraj Master, MD, PhD, FACS is Professor and Fray F. Marshall Chair in Clinical Urologic Research in the Department of Urology at Emory University School of Medicine, Associate Chair for Clinical Affairs and Quality, and Director of Clinical Research Unit. He is a diplomate of the American Board of Urology and a Fellow of the American College of Surgery.Dr. Master's primary clinical interest is urologic oncology, in particular kidney cancer, adrenal tumors, testicular cancer, high-risk prostate cancer and penile cancers.As Director of Clinical Research in the Department of Urology, he is active in investigating the role of inflammation in cancers and in researching "host" (patient) interaction with the disease. In his role as Associate Chair for Clinical Affairs and Quality, he works closelywith all faculty members towards a common goal of providing the highest quality of care to our patients. Emory University Hospital ranks as the number one hospital, out of 187, in both Georgia and metro Atlanta (U.S. News & World Report), and the Department of Urology ranks as one of Emory's top ten high-performing adult specialty areas.Dr. Master serves as an expert advisor to the American Cancer Society on prostate cancer and to the International Consultation on Urologic Diseases on kidney cancer. He has lectured both nationally and internationally. He is closely involved in teaching and mentoring medical students, urology residents and post-graduate fellows.In addition to his dedication to Emory patients, Dr. Master is also involved in humanitarianism outside Emory. On an annual basis, he volunteers his time to join a team of Emory medical students to Haiti. The team provides free urologic care including surgical treatment to indigent Haitian patients with urologic conditions.Following his undergraduate education at Northwestern University, Dr. Master attended medical school at the University of Chicago where he received both MD and PhD degrees. He completed his urology residency and two fellowships training at the University of California in San Francisco (UCSF) before joining the Department of Urology at Emory University in 2005.

Dr. Vincent Mellnick is board certified in Diagnostic Radiology and is an Assistant Professor of Radiology, Division of Diagnostic Radiology, Section of Abdominal Imaging, at Washington University School of Medicine. He currently practices at Washington University and is affiliated with Barnes Jewish Hospital. His focus is in Emergency, abdominal and diagnostic imaging.

Dr. Monica Morrow is Anne Burnett Windfohr Chair of Clinical Oncology, Professor of Surgery at Memorial Sloan Kettering Cancer Center. She is a surgical oncologist with a practice dedicated to the treatment of breast cancer. Her research has focused on how to apply the advances from clinical trials to daily surgical practice. Her research interests include how treatment choices for breast cancer surgery are made and identifying factors which predict for successful lumpectomy.

Dr. Ajay Nooka is an Associate Professor in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University. He earned his medical degree from Andhra Medical College in India before relocating to the United States. He received a Masters’ in Public Health from the University of Texas School of Public Health in Houston, Texas and then completed his internship and residency at the Northeastern Ohio University College of Medicine, Ohio. He pursued a fellowship in Hematology and Oncology at Emory University School of Medicine in Atlanta, Georgia where he also served as Chief Fellow before he joined faculty. Board certified in Hematology and Medical oncology, Dr. Nooka primarily focuses on multiple myeloma treatment and research. He is the Scientific Director of Data and Technology Applications at Winship Cancer Institute and chairs the Myeloma Working Group at Department of Hematology & Oncology, Emory University. He is involved in numerous professional organizations, including the International Myeloma Working Group of International Myeloma Society, American Society of Clinical Oncology, the American Society of Hematology, and the American Society for Transplantation and Cellular Therapies. Dr. Nooka’s interests as a clinical investigator focuses on multiple myeloma and bone marrow transplant. His research interests include integrating genomic and clinical data on a uniform platform to risk-stratify myeloma; and evaluate newer myeloma therapeutic strategies aimed at prolonging survival in myeloma patients. In addition to leading several investigator-initiated and industry-sponsored clinical trials, he is a recipient of several awards and grants including the Multiple Myeloma Research Foundation Accelerator Award and the International Myeloma Foundation Research Grants. He has published more than 250 articles and abstracts in high quality peer-reviewed journals including New England Journal of Medicine, Journal of Clinical Oncology, Blood, Leukemia, Lancet Oncology, and Cancer. In addition, he served as grant reviewer for several federally funded studies and served on the editorial board of the American Journal of Clinical Oncology and as an invited or ad hoc reviewer for several prestigious journals includingJournal of Clinical Oncology, Lancet Oncology, Leukemia, American Journal of Hematology, Cancer, British Journal of Hematology, Clinical Lymphoma, Myeloma and Leukemia, Bone Marrow Transplantation and Biology of Blood and Marrow Transplantation.

Dr. Anne O'Dea is certified by the American Board of Internal Medicine with sub certification in hematology and medical oncology. She completed a fellowship at the University of Kansas Medical Center. She earned her medical degree from the University of Kansas School of Medicine and completed her residency at the University of Kansas Medical Center.

Dr. Ruth O’Regan, M.B.B.Ch., B.A.O., is the Chair of Medicine and Charles A. Dewey Professor at the University of Rochester. She additionally serves as Physician-in-Chief of Strong Memorial Hospital and as Associate Director of Education and Mentoring at the Wilmot Cancer Institute at University of Rochester. She previously was Division Chief of Hematology, Medical Oncology and Palliative Care in the Department of Medicine and as Deputy Director at the Carbone Cancer Center at the University of Wisconsin School of Medicine and Public Health (UWSMPH). She served as Chief Scientific officer of the Big Ten Cancer Research Consortium guiding the research and scientific mission of the consortium and as Vice-Chair of the National Comprehensive Cancer Network Board of Directors. Prior to joining the faculty at UWSMPH she was Director of the Glenn Family Breast Cancer Program at the Winship Cancer Institute and as Vice-Chair for Education and Director of the Hematology Oncology Fellowship program in the Department of Hematology and Medical Oncology at Emory University. She additionally served as Chief of Hematology and Medical Oncology at the Georgia Cancer Center for Excellence at Grady Memorial Hospital. Dr. O’Regan earned her Medical Degree from University College, Dublin, Ireland and completed her Internal Medicine residency at the Medical College of Wisconsin and her Hematology/Oncology fellowship at Northwestern University. Her research program focuses on identifying mechanisms of resistance to breast-cancer therapies and on the development of new therapies with a specific focus on triple negative breast cancer. Dr. O’Regan is an internationally recognized breast cancer physician and researcher and is ranked by Newsweek/Castle Connolly Medical as one of the top oncologists in the nation. She is the Chief Scientific officer (CSO) of the Big Ten Cancer Research Consortium (Big Ten CRC) where she guides the research and scientific mission of the consortium and works closely with the Steering Committee and Clinical Trial Working Groups to identify and support the most promising clinical trials to be conducted through the consortium.

Joyce A. O’Shaughnessy, M.D. focuses on breast cancer prevention and treatment. She is Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center and for The US Oncology Network and is a member of the Scientific Advisory Board for US Oncology Research Network. Dr. O’Shaughnessy received her M.D. from Yale University Medical School. Her internship and residency in internal medicine were completed at Massachusetts General Hospital in 1985. She concluded a fellowship in medical oncology at the National Cancer Institute in 1987 and was a Senior Investigator there until 1995. Dr. O’Shaughnessy is a member of American Association for Cancer Research; American Society of Clinical Oncology; American Medical Women’s Association; American Medical Association; American College of Physicians; and Women in Cancer Research. Dr. O’Shaughnessy is an Associate Editor, Clinical Breast Cancer Journal; founder, The School of Breast Oncology. In 2009 D Magazine elected Dr. O’Shaughnessy as one of the best hematology oncologists in Dallas, Texas.

Pretesh Patel, MD, is an Associate Professor in the Department of Radiation Oncology at Emory University School of Medicine. Board certified in radiation oncology, Dr. Patel specializes in the treatment of pancreatic cancer, colorectal cancer, liver cancer, anal cancer, bladder cancer, kidney cancer, prostate cancer, and testicular cancer. Dr. Patel also focuses on the use of high-dose rate brachytherapy, stereotactic body radiation therapy and proton therapy. Dr. Patel is the residency program director in the Department of Radiation Oncology. He is actively involved in teaching and research activities for the residency program and for rotating medical students. Dr. Patel is a member of multiple professional organizations including the American Society for Radiation Oncology, the Radiologic Society of North America and the American Brachytherapy Society. Dr. Patel completed medical school and residency in radiation oncology at Duke University. In his final year of residency, Dr. Patel served as chief resident. He earned a BS in Computer Science at Duke University and graduated magna cum laude. Dr. Patel's research interests include clinical trials for gastrointestinal cancers, novel uses for HDR brachytherapy in genitourinary malignancies, as well as advancements in clinical and technical aspects of SBRT. He is also interested in the use of information technology to improve quality and safety in oncology clinical practice.

Dr. Mark D. Pegram is the Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology at the Stanford University School of Medicine. He currently serves as the Associate Director of Clinical Research at the Stanford Comprehensive Cancer Institute (SCCI). He also serves as the Associate Dean for Clinical Research Quality at the Stanford University School of Medicine, and is the Medical Director of the Stanford Clinical Translational Research Unit – a unit specializing in first-in-human phase I clinical trials Dr Pegram’s breast cancer research is focused on the study of the cancer-associated gene that encodes HER2 and on the development of novel agents in the treatment of patients with HER2-positive metastatic breast cancer.

Dr. Pishvaian is Associate Professor in the Department of Oncology, and Director of the Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs at theNCR Kimmel Cancer Center at Sibley Memorial Hospital at Johns Hopkins University School of Medicine.Formerly, Dr. Pishvaian was Associate Professor, in the Department of Gastrointestinal Oncology, and Co-director for Clinical Research at the Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research at the University of Texas, MD AndersonCancer Center.Dr. Pishvaian is an MD and a PhD in Tumor Biology and earned both degrees at Georgetown in 2001. He remained at Georgetown after graduation, completing his medical residency in 2004, then his fellowship in Hematology/Oncology in 2007. He served on the faculty at Georgetown until moving to MD Anderson in 2019.Dr. Pishvaian is a translational oncologist, focused on providing novel therapy for patients, particularly in the areas of pancreatic cancer and refractory colorectal cancer. His work has been focused in the area of precision medicine, with a special focus on therapy targeted towards homologous recombination DNA repair deficient tumors, and Dr. Pishvaian is a Co-investigator on an NIH RO1 to study mechanisms of resistance to PARP inhibitor-based therapy.

Dr. Pollyea is Associate Professor of Medicine and is also the Clinical Director of Leukemia Services at the University of Colorado. Dr. Pollyea has served as the Principal Investigator of multiple early-phase clinical trials, and has received funding for his work from the American Society of Hematology, the American Society of Clinical Oncology and the Leukemia and Lymphoma Society. He is the Chair of the NCCN AML Committee, and has over 100 peer-reviewed publications.

Steven Poplack, M.D. is a diagnostic radiologist specializing in breast imaging. He is a professor of radiology at Stanford University School of Medicine. Dr. Poplack completed his residency at Yale New-Haven Hospital. He worked as a diagnostic radiologist and breast radiologist at Dartmouth Hitchcock Medical Center from 1993-2014, as a breast radiologist at Mallinckrodt institute of radiology at Washington University in St. Louis from 2015-2020, and currently practices at Stanford Health Care in Palo Alto, CA. Dr. Poplack is board certified in Diagnostic Radiology. He is a fellow of the American College of Radiology and Society of Breast Imaging.

Dr. Puri is board certified in thoracic surgery and general surgery. He earned his medical degree from All India Institute of Medical Sciences in New Delhi, India. He continued his education with a residence in general surgery at Creighton University Medical Center in Omaha, Nebraska. As well as a fellowship in thoracic surgery at Barnes-Jewish Hospital in St. Louis, Toronto General Hospital in Toronto, and Memorial Sloan Kettering Cancer Center in New York.

Suresh S. Ramalingam is Professor of Hematology and Medical Oncology and the Roberto C. Goizueta Chair for Cancer Research at the Emory University School of Medicine. He is also the Deputy Director of the Winship Cancer Institute of Emory University Dr. Ramalingam’s research is focused on the development of novel treatment approaches for patients with lung cancer. He has published more than 325 original manuscripts, review articles, editorials and book chapters. He serves the principal investigator for the Emory University Lung Cancer SPORE award from the National Cancer Institute. He is also the contact principal investigator for the ECOG-ACRIN Thoracic Malignancies Translational Science Center Award from the National Cancer Institute. Dr. Ramalingam serves as the Chair of the ECOG-ACRIN Thoracic Malignancies Committee. He is the section editor for ‘Chest malignancies’ for ‘Cancer’ journal. In addition, he serves on the editorial board for Annals of Oncology, Journal of the National Cancer Institute and Clinical Lung Cancer. Dr. Ramalingam is the recipient of several awards, including the James R. Eckman Award for Excellence at Emory University, and the Distinguished Cancer Scholar Award, Georgia Cancer Coalition. In addition, he is a recipient of the ASCO Career Development Award (2006–2009), the ECOG Young Investigator Award (2013), and the NCI Clinical Investigators Team Leadership Award (2010-12). Dr. Ramalingam serves as a member of the board of directors for the International Association for the Study of Lung Cancer (IASLC) and as a member of the NCI Thoracic Malignancies Steering Committee. Dr. Ramalingam received his medical degree at Kilpauk Medical College, Madras, India. He completed his residency in Internal Medicine at Wayne State University, Detroit, MI, where he also served as Chief Medical Resident. He then completed a fellowship in Hematology and Medical Oncology at the University of Pittsburgh Medical Center, Pittsburgh, PA

Dr. Matthew Rettig is a Professor of Medicine and Urology at the David Geffen School of Medicine at UCLA, where he serves as the Medical Director of the Prostate Cancer Program, and is the Chief of the Division of Hematology and Oncology at the VA Greater Los Angeles. As a medical oncologist with a special emphasis on the management of patients with advanced prostate cancer, Dr. Rettig has a keen interest in the development and translation of novel therapeutics and diagnostic approaches for lethal prostate cancer. He has and continues to serve as the PI on numerous phase 1, 2 and 3 clinical trials that span the prostate cancer space from neoadjuvant studies to trials in heavily pre-treated metastatic castration resistant prostate cancer patients. His laboratory and clinical research are actively supported by multiple funding agencies, including the National Cancer Institute, the Department of Defense, the Department of Veterans Affairs and several foundations.

Dr. Rini is a Professor of Medicine at Vanderbilt University in Nashville, TN. Dr. Rini is the Chief of Clinical Trials for the Vanderbilt Ingram Cancer Center (VICC). Dr. Rini earned his medical degree at the Ohio State University College of Medicine in Columbus, Ohio. After completing a residency program in internal medicine at University of Chicago Hospitals in Illinois, Dr. Rini was awarded a fellowship in hematology and oncology at the University of Chicago. Dr. Rini was an Assistant Professor at the University of California San Francisco before moving to Cleveland Clinic in 2005. Dr. Rini led the Genitourinary cancer program at Cleveland Clinic and was integrally involved in drug development in RCC, leading several pivotal trials that led to FDA approval. Dr. Rini moved to Vanderbilt in 2020 to continue his RCC research and oversee clinical trials at the VICC. Dr. Rini’s primary research has been in renal cell carcinoma (RCC), with special focus on antiangiogenic therapy and immunotherapy. Dr. Rini’s research has been published in peer-reviewed journals that include the New England Journal of Medicine, Journal of the National Cancer Institute, Journal of Clinical Oncology, Lancet and the Journal of the American Medical Association. Dr. Rini is certified in Medical Oncology by the American Board of Internal Medicine, Dr. Rini is active in numerous professional organizations including ASCO, the Society for Immunotherapy of Cancer (SITC), the Kidney Cancer Association (KCA) and is past Chair of the Oncologic Drugs Advisory Committee (ODAC).

Clifford G. Robinson, MD is a Professor of Radiation Oncology. Dr. Robinson earned a medical degree from Case Western Reserve University School of Medicine in 2004. He joined the faculty in 2009 after completing residency at the Cleveland Clinic where he served as chief resident. He is Chief of the Stereotactic Body Radiation Therapy (SBRT) and Cardiothoracic Radiation Oncology services, and Director of Clinical Trials for Radiation Oncology. His clinical practice and research interests are thoracic oncology, neuro oncology, stereotactic body radiotherapy, and radiosurgery/Gamma Knife.

Dr. Schiller is the Director of the Hematological Malignancy/ Stem Cell Transplant Program at the David Geffen School of Medicine at UCLA, supervising 200 transplants per year in 2018 and 2019. He has extensive clinical research experience, having conducted many investigator-initiated and multicenter trials, mostly in Hematologic Malignancies as well as Blood and Marrow Transplantation. He is immediate past Chair of the Faculty Executive Committee for the School of Medicine at UCLA. He is an author of over 190 publications and 350 abstracts and presented in more than 340 events. He has mentored residents, medical students, and fellows for more than 30 years. He has also served as a member and Chair of the Committee on Training for the American Society of Hematology and worked with its Trainee Council developing programs for the national meeting of the Society and curriculum for its Trainee Day and is presently Vice-Chair of the ASH Foundation committee. Dr. Schiller has an outstanding track record in clinical research, teaching, and mentoring and was co-investigator on Alternative Training grant for Bone Marrow Failure syndromes. He also has extensive experience outside of medicine, with nonprofit, charitable institutions. He has served on the Board of Trustees of Wilshire Boulevard Temple, and was Chairman of the Los Angeles Museum of the Holocaust. Dr. Schiller has over 30 years of experience in the diagnosis and management of adults with Hematologic Malignancies and those undergoing allogeneic stem cell transplantation for non-malignant disorders including sickle cell disease.

David M. Schuster, MD, is Professor in the Department of Radiology and Imaging Sciences at Emory University School of Medicine. Dr. Schuster serves as Director of the Division of Nuclear Medicine and Molecular Imaging, and is a Georgia Research Alliance Distinguished Scientist. Board certified in radiology and nuclear medicine, he specializes in molecular medicine and integrative imaging.

Chirag Shah, MD, is an Associate Professor and Staff in the Department of Radiation Oncology at the Cleveland Clinic. He also serves as Director of Breast Radiation Oncology and Director of Clinical Research. Dr. Shah received his Bachelor's degree from Youngstown State University and his Medical degree from Northeast Ohio Medical University. He completed his internship, and residency at William Beaumont Hospital from 2007 to 2012 and joined the Cleveland Clinic Staff in 2015.Dr. Shah serves as a reviewer for various medical journals and is a member of various medical societies. His primary research interests are breast cancer, sarcoma, prostate cancer, lymphoma, and innovative radiation treatment schedules as well as lymphedema. He has participated in numerous in-house, pharmaceutical and cooperative group trials.

Dr. Cary Lynn Siegel is a professor of radiology at Washington University School of Medicine. Dr. Siegel has an extensive and broad scientific background in genitourinary radiology, imaging evaluation of testicular cancer, the feasibility of MR diffusion studies in the kidney, identification of crossing vessels at the ureteropelvic junction, ultrasound of renal cell carcinoma, preoperative assessment of UPJ obstruction with endoluminal US and helical CT, evaluation of cystic renal mass, MR and ultrasound evaluation of the female urethra, and MR imaging of female pelvic floor dysfunction.

Dr. Slovin is Attending Physician in the Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and Professor of Medicine, Department of Medicine at Joan and Sanford I. Weill Medical College of Cornell University. She earned her doctorate in pathobiology from Columbia University and her medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. Her postdoctoral training included a research fellowship in clinical immunology at Scripps Clinic & Research Foundation, La Jolla, California; an internship and a residency in internal medicine from The Mount Sinai Hospital in New York; and a hematology/oncology fellowship in the Department of Medicine, Memorial Sloan-Kettering Cancer Center. She is a board-certified medical oncologist with expertise in the areas of prostate cancer immunology and clinical trial design. A noted immunologist, her research focuses on the development of novel immunologic approaches for the treatment of prostate cancer. This includes assuming the leadership of the Prostate Immunotherapy Group sponsored by the Prostate Cancer Foundation whose challenge is to develop guidelines for development of immune therapy clinical trials in prostate cancer. She has multiple administrative roles at MSK including, Associate Chair of Academic Affairs in the Department of Medicine, Director of Genitourinary Oncology Education and Associate Chair of the MSK Institution Review Board. She is a member of several professional associations, including the American Society of Clinical Oncology, American Association of Immunologists, American Association of Investigative Pathology, and American Association of Cancer Researchers, American Urologic Association and Sigma Xi Research Society. An ad hoc reviewer for numerous journals, including Cancer, Cancer Immunology and Immunotherapy, JAMA, Cancer Research, and Clinical Cancer Research, New England Journal of Medicine, Urology and Journal of Urology, she also served as Associate Editor for Seminars in Oncology as well as the editorial boards of several major journals including Clinical Cancer Research. She has served as member of the NCI Clinical Oncology Study Section, ad hoc reviewer for the DOD, AACR, and NCI SPORE panels and was Chair of the VA Merit Grant Review System. Dr Slovin is well-recognized in the area of prostate cancer immunotherapy and has contributed many peer-reviewed articles and reviews to the medical literature. She has received numerous accolades and was recognized by CancerCare as one of their Physicians of the Year. She has been a keynote speaker at the Massachusetts Prostate Cancer Coalition. She has received numerous teaching awards from the MSK Department of Medicine as well as from Weill-Cornell Medical College.

Dr. Mark A. Socinski is the Executive Medical Director of the AdventHealth Cancer Institute. Dr. Socinski is a board-certified, fellowship-trained medical oncologist, specializing in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. He is an internationally recognized expert in the development of novel chemotherapy agents and treatment strategies for advanced non-small cell lung cancer and small-cell lung cancer. His research has focused on incorporating personalized medicine and molecular biomarkers in the treatment of lung cancer. Dr. Socinski received his medical degree from the University of Vermont in Burlington, VT. He completed his medical residency in internal medicine at Beth Israel Hospital/Harvard Medical School and completed training in medical oncology at the Dana-Farber Cancer Institute/Harvard Medical School. Dr. Socinski holds memberships in numerous professional societies such as the American College of Physicians, American Society of Clinical Oncology, International Association for the Study of Lung Cancer, and the American College of Chest Physicians. He formerly served as co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute. Dr. Socinski was instrumental to the success of the multidisciplinary thoracic oncology programs at both the University of North Carolina and the University of Pittsburgh prior to accepting his current position at AdventHealth in 2016.

Dr Stinchcombe completed medical school at the University of Virginia, his internal medicine residency at the University of Michigan, and his hematology and oncology fellowship at the University of North Carolina. His clinical interest is in thoracic malignancies, and his research focus is clinical trials for non-small-cell and small-cell lung cancer. He is a member of Duke Cancer Institute, and Thoracic Oncology Program at Duke University, Durham, NC.

Michael J. Thirman, MD, specializes in the medical management of adults with hematologic disorders, leukemia, lymphoma, myelodysplastic syndromes, and myeloproliferative disorders. His laboratory focuses on the role of MLL fusion proteins in the development of leukemia. The overall goals of his research are to understand the mechanisms that mediate transformation of normal hematopoietic stem cells and to develop targeted therapies based on these insights. Dr. Thirman also directs clinical trials in acute myeloid leukemia and chronic lymphocytic leukemia.An active researcher, Dr. Thirman has published more than 65 papers, reviews, and book chapters on clinical and laboratory studies in leukemia and lymphoma. He serves on the editorial board of Blood Advances, the Medical Advisory Board of the Leukemia Research Foundation, and the Board of Trustees of the Illinois chapter of the Leukemia and Lymphoma Society. He is a recipient of the Stohlman Scholar Award by the Leukemia and Lymphoma Society and was selected as a Chicago Magazine Top Cancer Doctor.

Dr. Frank A. Vicini has held multiple academic appointments and has been involved in numerous clinical research studies involving breast and prostate cancer. He has designed, developed and completed numerous phase I/II and III NIH/NCI clinical trials to evaluate new and improved techniques to treat patients with Stage I and II breast cancer. Dr. Vicini has authored over 300 peer-reviewed articles and presented his research at national and international meetings. He is a visiting professor in both the United States and Europe, authored multiple chapters in textbooks and is on the editorial board of several oncology journals. In addition, he is listed as one of the few oncologists in “Best Oncology Doctors in America.” Dr. Vicini was recently named Genesis Care National Principal Investigator.

Dr. Wainberg an academic medical oncologist at the David Geffen UCLA School of Medicine specializing in gastrointestinal malignancies. He currently serve as the co-director of the GI oncology program and medical director of the Colorectal Cancer Center at UCLA with a joint appointment in medicine and surgery. He completed my fellowship at UCLA and spent an additional two years training at UCLA in the GI oncology program area. His research focus is on translational research of GI cancers with a particular focus on drug development. He also serve as the director of the Early Phase Clinical Research Program at the Jonsson Comprehensive Cancer Center at UCLA. He is currently the principal investigator on over 25 clinical trials focused on targeted therapeutics in patients with gastrointestinal cancers. As PI or co-Investigator on several state and federally funded grants, Dr. Wainberg played a key role in the acquisition of tissue samples and their analysis. He performed some of the first work characterizing the role of several targeted therapeutics in gastric cancer models. These experiments along with other trials listed below were critical for the launching of the several large clinical trials. He currently serve on the ASCO Scientific Program Committee for GI cancer (non-colorectal) and is on several steering committees of large randomized trials. Most recently, Dr. Wainberg has served as director of the Early Phase Clinical Research program within the Jonsson Comprehensive Cancer Center (JCCC). This involves the coordination and monitoring of all early phase clinical research supported by the JCCC. They recently underwent our NCI-mandated 5-year renewal at which, presented progress over the last 5 years. In addition to this role, Dr. Wainberg currently the principal investigator on many Phase 1 protocols at UCLA including many first-in-human therapeutics that are poised for further clinical development. During his period as director, they have significantly expanded the number of trials we support and have dramatically increased the number of subjects we enroll. This has included far greater cooperation and translation of pre-clinical ideas from various departments. He has recently been involved with helping obtain several FDA approvals including pembrolizumab for gastric cancer and pexidartinib for TGCT. Dr. Wainberg testified in front of the FDA and several of these have recently been published in prestigious journals such as New England Journal of Medicine and Journal of Clinical Oncology.

Dr. Weiser is the incumbent of the Stuart H.Q. Quan Chair in Colorectal Surgery and an Attending Surgeon on the Colorectal Service at Memorial Sloan Kettering Cancer Center. He is Professor of Surgery at Weill Cornell Medical College. Dr. Weiser received his MD degree from the University Of Chicago and completed residency at Brigham and Women’s Hospital. He has completed fellowships in surgical research (Harvard Medical School), surgical oncology (Memorial Sloan Kettering Cancer Center) and colorectal surgery (Mount Sinai Hospital, New York). Dr. Weiser serves as Vice Chair for Faculty Affairs and Chair of the OR Executive Committee in the Department of Surgery and has recently served as the Medical Staff President, Memorial Sloan Kettering Cancer Center. He is the Colorectal Surgery section editor for Up-To-Date and the Annals of Surgical Oncology. Dr. Weiser has been elected to the Southern Surgical Association and the American Surgical Association. He is a fellow of the American College of Surgeons, Society of Surgical Oncology and American Society of Colon and Rectal Surgeons. Dr. Weiser’s research interests include modeling outcome and colorectal cancer staging, tumor profiling including circulating tumor DNA, multimodality treatment of colorectal cancer, minimally invasive and robotic surgery. He is the surgical lead on the PROSPECT trial, a cooperative group prospective randomized trial investigating neoadjuvant therapy for rectal cancer. He has been appointed to the ASCRS Fundamentals of Rectal Cancer Surgery Committee, American Joint Committee on Cancer (AJCC) Colorectal Staging Taskforce (7th and 8th editions), and the AJCC Precision Medicine Committee. He has served as Chair of the Colorectal Task Group for the Society of Surgical Oncology (SSO) and as Colorectal Track Leader for the Education Committee of the American Society of Clinical Oncology (ASCO). Dr. Weiser has mentored over 30 clinical and laboratory research fellows and has published over 225 peer review articles and over 100 review articles, book chapters, and editorials.

Dr. West is a thoracic oncology specialist and Associate Clinical Professor in Medical Oncology at City of Hope Cancer Center. He also serves as Clinical Executive Director of AccessHope, providing remote cancer consult services. Dr. West received an MPhil in Experimental Biology from Cambridge University on a Fulbright Scholarship and MD from Harvard Medical School. His internship and residency in internal medicine were at Harvard’s Brigham and Women’s Hospital, followed by medical oncology fellowship at the Fred Hutchinson Cancer Research Center in Seattle, WA. After co-leading thoracic oncology at Swedish Cancer Institute in Seattle for over 16 years, in 2019 he moved to the City of Hope to dedicate his focus on innovative approaches to delivering sub-specialist expertise across a broader geography, using tools such as remote case reviews and telemedicine consultations. He has authored dozens of papers and chairs several CME programs and symposia internationally on thoracic oncology, novel educational approaches, and social media in cancer care. Dr. West is also Founder & President of Global Resource for Advancing Cancer Education (GRACE); Web Editor for JAMA Oncology; a regular correspondent for Medscape; and contributing author and section editor in lung cancer for UpToDate.

Norman Wolmark, MD, is chairman of the NSABP Foundation and chair and contact principal investigator of NRG Oncology, one of five research groups in the NSI's National Clinical Trials Network. He is currently Professor of Surgery and Director of NCI Cooperative Group Clinical Trials at the UPMC Hillman Cancer Center and the University of Pittsburgh. Dr. Wolmark has spent decades conducting groundbreaking research and early clinical trials in the treatment of breast and bowel cancers. Much of his early studies were conducted at UPMC and the University of Pittsburgh alongside Bernard Fisher, M.D., one of the founders of NSABP. Findings from the NSABP Trials led to the establishment of lumpectomy plus radiotherapy over radical mastectomy as the standard surgical treatment for breast cancer; were the first to demonstrate that adjuvant chemotherapy could alter the natural history of breast cancer, increasing survival rates; and were the first to demonstrate on a large scale that preventative effects of the drug tamoxifen and raloxifene in breast cancer. Dr. Wolmark is a Fellow of the American College of Surgeons and of the Royal College of Surgeons (Canada) and a member of a number of professional associations and organizations including the American Society for Clinical Oncology , the American Association of Cancer Research, and the American Surgical Association. He has authored more than 400 scientific publications and has served bin the editorial boards of the Journal of Clinical oncology, The New England Journal of Medicine, and Breast cancer Research and Treatment.

Dr. Collins graduated from the University of Florida with a Bachelor of Science in Biology and again with her Master of Science in Human Nutrition. She started her career with the National Institute of Health Clinical Research Center in Charlottesville, VA. In 2007 she graduated from the University of Tennessee, Knoxville with her Ph.D. in Experimental Psychology after defending her research dissertation: “Hope, Coping Style, Quality of Life, Knowledge about Cancer and risk for Dietary Deficiency in Patients with Total Gastrectomy for Stomach Cancer.” She is also a registered dietitian with the Academy of Nutrition and Dietetics. She belongs to the Oncology DPG and Dietitians in Integrative and Functional Medicine (DIFM). Presentations include Dietary Intake, Coping Style and Quality of Life in Patients Undergoing Radiation Treatment(American Institute of Cancer Research) and Keep It Healthy –Be Fit and Flourish a Breast Cancer Survivorship Program (FNCE). Dr. Collins is on advisory boards for Keiser University and teaches a wide variety of classes on the college level in both psychology and nutrition fields. She is owner of CB7, LLC DBA Creation Balance and CSC. Dr. Collins hosts her own podcasts with physician/cancer survivor interviews can be found on YouTube and Spotify.